Karlsson I, Ekdahl A, Etchingham-Coll H, Li X, Ericsson C, Ahlqvist M
Int J Mol Sci. 2025; 26(3).
PMID: 39940909
PMC: 11818726.
DOI: 10.3390/ijms26031141.
Shishido Y, Yoshida T, Oshida K, Uchida M
Pharmacol Res Perspect. 2024; 12(5):e70017.
PMID: 39312270
PMC: 11418634.
DOI: 10.1002/prp2.70017.
Lee S, Verkhoturov D, Eller M, Verkhoturov S, Shaw M, Gwon K
ACS Nano. 2023; 17(23):23584-23594.
PMID: 38033295
PMC: 10985841.
DOI: 10.1021/acsnano.3c06604.
Ock S, Kim S, Ju W, Kim Y, Wi H, Lee P
Int J Mol Sci. 2023; 24(20).
PMID: 37895114
PMC: 10607770.
DOI: 10.3390/ijms242015429.
Arakawa H, Nakazono Y, Matsuoka N, Hayashi M, Shirasaka Y, Hirao A
Commun Biol. 2023; 6(1):866.
PMID: 37608051
PMC: 10444810.
DOI: 10.1038/s42003-023-05216-z.
Guiding Hepatic Differentiation of Pluripotent Stem Cells Using 3D Microfluidic Co-Cultures with Human Hepatocytes.
Fattahi P, de Hoyos-Vega J, Choi J, Duffy C, Gonzalez-Suarez A, Ishida Y
Cells. 2023; 12(15).
PMID: 37566061
PMC: 10417547.
DOI: 10.3390/cells12151982.
Function of hepatocyte spheroids in bioactive microcapsules is enhanced by endogenous and exogenous hepatocyte growth factor.
Gwon K, Choi D, de Hoyos-Vega J, Baskaran H, Gonzalez-Suarez A, Lee S
Bioact Mater. 2023; 28:183-195.
PMID: 37266448
PMC: 10230170.
DOI: 10.1016/j.bioactmat.2023.05.009.
Characterization of the humanized FRG mouse model and development of an AAV-LK03 variant with improved liver lobular biodistribution.
Cabanes-Creus M, Navarro R, Liao S, Scott S, Carlessi R, Roca-Pinilla R
Mol Ther Methods Clin Dev. 2023; 28:220-237.
PMID: 36700121
PMC: 9860073.
DOI: 10.1016/j.omtm.2022.12.014.
Consideration of Commercially Available Hepatocytes as Cell Sources for Liver-Microphysiological Systems by Comparing Liver Characteristics.
Horiuchi S, Kuroda Y, Komizu Y, Ishida S
Pharmaceutics. 2023; 15(1).
PMID: 36678684
PMC: 9867117.
DOI: 10.3390/pharmaceutics15010055.
Proteomic analysis of hepatic effects of phenobarbital in mice with humanized liver.
Sprenger H, Rasinger J, Hammer H, Naboulsi W, Zabinsky E, Planatscher H
Arch Toxicol. 2022; 96(10):2739-2754.
PMID: 35881160
PMC: 9352639.
DOI: 10.1007/s00204-022-03338-7.
Contribution of Humanized Liver Chimeric Mice to the Study of Human Hepatic Drug Transporters: State of the Art and Perspectives.
Zerdoug A, Le Vee M, Uehara S, Lopez B, Chesne C, Suemizu H
Eur J Drug Metab Pharmacokinet. 2022; 47(5):621-637.
PMID: 35793042
DOI: 10.1007/s13318-022-00782-9.
Effect of sex-specific differences on function of induced hepatocyte-like cells generated from male and female mouse embryonic fibroblasts.
Ullah I, Shin Y, Kim Y, Oh K, Hwang S, Kim Y
Stem Cell Res Ther. 2021; 12(1):79.
PMID: 33494802
PMC: 7831237.
DOI: 10.1186/s13287-020-02100-z.
Detection of acute toxicity of aflatoxin B1 to human hepatocytes in vitro and in vivo using chimeric mice with humanized livers.
Ishida Y, Yamasaki C, Iwanari H, Yamashita H, Ogawa Y, Yanagi A
PLoS One. 2020; 15(9):e0239540.
PMID: 32966316
PMC: 7510964.
DOI: 10.1371/journal.pone.0239540.
Culture density contributes to hepatic functions of fresh human hepatocytes isolated from chimeric mice with humanized livers: Novel, long-term, functional two-dimensional in vitro tool for developing new drugs.
Yamasaki C, Ishida Y, Yanagi A, Yoshizane Y, Kojima Y, Ogawa Y
PLoS One. 2020; 15(9):e0237809.
PMID: 32915792
PMC: 7485858.
DOI: 10.1371/journal.pone.0237809.
Orchestration of Intracellular Circuits by G Protein-Coupled Receptor 39 for Hepatitis B Virus Proliferation.
Goto K, Nishitsuji H, Sugiyama M, Nishida N, Mizokami M, Shimotohno K
Int J Mol Sci. 2020; 21(16).
PMID: 32784555
PMC: 7460832.
DOI: 10.3390/ijms21165661.
Characterization and applications of chimeric mice with humanized livers for preclinical drug development.
Tateno C, Kojima Y
Lab Anim Res. 2020; 36:2.
PMID: 32206609
PMC: 7081693.
DOI: 10.1186/s42826-019-0032-y.
Art of Making Artificial Liver: Depicting Human Liver Biology and Diseases in Mice.
Sugahara G, Ishida Y, Sun J, Tateno C, Saito T
Semin Liver Dis. 2020; 40(2):189-212.
PMID: 32074631
PMC: 8629128.
DOI: 10.1055/s-0040-1701444.
Novel therapeutic features of disulfiram against hepatocellular carcinoma cells with inhibitory effects on a disintegrin and metalloproteinase 10.
Goto K, Arai J, Stephanou A, Kato N
Oncotarget. 2018; 9(27):18821-18831.
PMID: 29721164
PMC: 5922358.
DOI: 10.18632/oncotarget.24568.
Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study.
Goto K, Annan D, Morita T, Li W, Muroyama R, Matsubara Y
Sci Rep. 2016; 6:38407.
PMID: 27910927
PMC: 5133582.
DOI: 10.1038/srep38407.
Anti-hepatocellular carcinoma properties of the anti-alcoholism drug disulfiram discovered to enzymatically inhibit the AMPK-related kinase SNARK in vitro.
Goto K, Kato N, Chung R
Oncotarget. 2016; 7(46):74987-74999.
PMID: 27602492
PMC: 5342717.
DOI: 10.18632/oncotarget.11820.